Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Aeglea BioTherapeutics, Inc. | agle-8k_20201105.htm |
Exhibit 99.1
Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights
Received U.S. Orphan Drug and Positive Opinion for EU Orphan Drug Designations for ACN00177
Continued Progress in Arginase 1 Deficiency Patient Identification and Engagement Efforts
Austin, Texas, November 5, 2020 - Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today reported its third quarter 2020 financial results, and provided recent corporate and program highlights.
“Although it’s been a challenging environment for biotech with the global pandemic, we have continued to be productive in our Arginase 1 Deficiency patient identification and engagement efforts. I am pleased with the progress we are making overall as well as specifically at our PEACE trial sites,” said Anthony Quinn, M.B Ch.B, Ph.D., president and chief executive officer of Aeglea. “I am also excited by the momentum we are building in our Homocystinuria program with the recent granting of U.S. Orphan Drug Designation and a positive opinion for EU Orphan Drug Designation for ACN00177.”
Recent Highlights and Updates
Pegzilarginase in Arginase 1 Deficiency
|
|
• |
In September, Aeglea announced the PEACE Phase 3 pivotal trial was more than 50% enrolled with nearly twice the number of patients needed to complete enrollment identified at active trial sites. Enrollment for the trial is anticipated to be completed in January 2021. |
|
|
• |
As of September, Aeglea has identified over 250 Arginase 1 Deficiency patients in addressable markets, a 25% increase relative to the prior year. The number of currently identified patients represents more than 50% and 30% of the estimated genetic prevalence populations in the U.S. and EU5, respectively. |
ACN00177 in Homocystinuria
|
|
• |
In October, Aeglea announced the U.S. Food and Drug Administration granted Orphan Drug Designation to ACN00177 for the treatment of Homocystinuria. |
|
|
• |
Additionally, the European Medicines Agency Committee for Orphan Medicinal Products issued a positive opinion recommending Orphan Drug Designation for ACN00177 for the treatment of Homocystinuria in the European Union. |
Corporate
|
|
• |
In October, the Company strengthened its financial position with proceeds from shares of common stock sold under its ATM program, resulting in gross proceeds of $25 million, extending its cash runway into 2023. |
Upcoming Events
Aeglea will be attending the following virtual investor conferences in the fourth quarter:
|
|
o |
Piper Sandler 32nd Annual Virtual Healthcare Conference, December 1-3 |
|
|
o |
3rd Annual Evercore ISI HealthCONx Conference, December 1-3 |
Third Quarter 2020 Financial Results
As of September 30, 2020, Aeglea had available cash, cash equivalents, marketable securities and restricted cash of $141.5 million. In addition, in October 2020 the Company raised approximately $24.6 million in net proceeds from shares of common stock sold under its ATM program. Based on Aeglea’s current operating plan, and taking into account the net offering proceeds, management believes it has sufficient capital resources to fund anticipated operations into 2023.
Research and development expenses totaled $12.5 million for the third quarter of 2020 and $17.8 million for the third quarter of 2019. The decrease was primarily associated with completing certain manufacturing and pre-commercial activities for Aeglea’s lead product candidate, pegzilarginase, completing a Phase 1/2 clinical trial in patients with Arginase 1 Deficiency and closing cancer trials; offset
by a ramp-up in manufacturing for ACN00177 in Homocystinuria and higher personnel-related expenses.
General and administrative expenses totaled $5.7 million for the third quarter of 2020 and $4.3 million for the third quarter of 2019. This increase was primarily due to ramping-up commercial capabilities and additional facilities to support company growth.
Net loss totaled $18.0 million and $21.6 million for the third quarter of 2020 and 2019, respectively, with non-cash stock compensation expense of $1.7 million and $1.4 million for the third quarter of 2020 and 2019, respectively.
About Pegzilarginase in Arginase 1 Deficiency
Pegzilarginase is an enhanced human arginase that enzymatically lowers levels of the amino acid arginine. Aeglea is developing pegzilarginase for the treatment of patients with Arginase 1 Deficiency (ARG1-D), a rare debilitating, progressive disease presenting in childhood with persistent hyperargininemia, spasticity, developmental delay, intellectual disability, seizures and early mortality. Pegzilarginase is intended for use as an enzyme therapy to reduce elevated blood arginine levels in patients with ARG1-D. Aeglea’s Phase 1/2 and Phase 2 open-label extension data for pegzilarginase in patients with ARG1-D demonstrated clinical improvements and sustained lowering of plasma arginine. The Company’s single, global pivotal Phase 3 PEACE trial is designed to assess the effects of treatment with pegzilarginase versus placebo over 24 weeks with a primary endpoint of plasma arginine reduction.
About ACN00177 in Homocystinuria
Aeglea is developing ACN00177 for the treatment of patients with cystathionine beta synthase (CBS) deficiency, also known as Classical Homocystinuria. Homocysteine accumulation plays a key role in multiple progressive and serious disease-related complications, including thromboembolic vascular events, skeletal abnormalities including severe osteoporosis, developmental delay, intellectual disability, lens dislocation and severe near-sightedness. ACN00177 has been designed as a novel recombinant human enzyme, which degrades the amino acid homocysteine and its related homocystine dimer. With this mechanism, ACN00177 is intended to lower the abnormally high blood levels of homocysteine in patients with Homocystinuria. Preclinical data demonstrated that ACN00177 improved important disease-related abnormalities and survival in a mouse model of Homocystinuria. The Company initiated a Phase 1/2 trial in the second quarter of 2020 and continues patient identification and administrative activities. The timing of first patient dosing in this Phase 1/2 trial will depend on determinations by individual sites as they adjust to impacts from COVID-19. ACN00177 has been granted Orphan Drug Designation by the U.S. FDA and received a positive opinion on Orphan Drug Designation from the European Medicines Agency.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designations. The Company initiated a Phase 1/2 clinical trial of ACN00177 for the treatment of Homocystinuria in the second quarter of 2020. Aeglea has an active discovery platform, with the most advanced program for Cystinuria. For more information, please visit http://aegleabio.com.
Safe Harbor / Forward Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our cash forecasts, the timing and success of our clinical trials and related data, the timing and expectations for regulatory submissions and approvals, timing and results of meetings with regulators, the timing of announcements and updates relating to our clinical trials and related data, our ability to enroll patients into our clinical trials, the expected impact of the COVID-19 pandemic on our operations and clinical trials, success in our collaborations, the potential addressable markets of the our product candidates and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Media Contact:
Kelly Boothe, Ph.D.
Director, Corporate Communications
Aeglea BioTherapeutics
512.399.5458
media@aegleabio.com
Investor Contact:
Joey Perrone
Senior Director, Finance & Investor Relations
Aeglea BioTherapeutics
investors@aegleabio.com
Aeglea BioTherapeutics, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands, except share and per share amounts)
|
|
|
September 30, |
|
|
December 31, |
|
||
|
|
|
2020 |
|
|
2019 |
|
||
|
ASSETS |
|
|
|
|
|
|
|
|
|
CURRENT ASSETS |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
54,223 |
|
|
$ |
19,253 |
|
|
Marketable securities |
|
|
85,753 |
|
|
|
52,696 |
|
|
Prepaid expenses and other current assets |
|
|
4,423 |
|
|
|
2,556 |
|
|
Total current assets |
|
|
144,399 |
|
|
|
74,505 |
|
|
Restricted cash |
|
|
1,500 |
|
|
|
1,500 |
|
|
Property and equipment, net |
|
|
5,216 |
|
|
|
2,385 |
|
|
Operating lease right-of-use assets |
|
|
4,394 |
|
|
|
4,726 |
|
|
Other non-current assets |
|
|
122 |
|
|
|
67 |
|
|
TOTAL ASSETS |
|
$ |
155,631 |
|
|
$ |
83,183 |
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
|
CURRENT LIABILITIES |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
2,295 |
|
|
$ |
3,154 |
|
|
Operating lease liabilities |
|
|
341 |
|
|
|
351 |
|
|
Accrued and other current liabilities |
|
|
11,713 |
|
|
|
14,854 |
|
|
Total current liabilities |
|
|
14,349 |
|
|
|
18,359 |
|
|
Non-current operating lease liabilities |
|
|
4,947 |
|
|
|
4,712 |
|
|
Other non-current liabilities |
|
|
61 |
|
|
|
31 |
|
|
TOTAL LIABILITIES |
|
|
19,357 |
|
|
|
23,102 |
|
|
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
|
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2020 and December 31, 2019; no shares issued and outstanding as of September 30, 2020 and December 31, 2019 |
|
|
— |
|
|
|
— |
|
|
Common stock, $0.0001 par value; 500,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 44,692,030 shares and 29,084,437 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively |
|
|
5 |
|
|
|
3 |
|
|
Additional paid-in capital |
|
|
389,543 |
|
|
|
255,142 |
|
|
Accumulated other comprehensive income |
|
|
20 |
|
|
|
51 |
|
|
Accumulated deficit |
|
|
(253,294 |
) |
|
|
(195,115 |
) |
|
TOTAL STOCKHOLDERS’ EQUITY |
|
|
136,274 |
|
|
|
60,081 |
|
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
$ |
155,631 |
|
|
$ |
83,183 |
|
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share amounts)
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
12,451 |
|
|
$ |
17,839 |
|
|
$ |
43,882 |
|
|
$ |
47,034 |
|
|
General and administrative |
|
|
5,672 |
|
|
|
4,307 |
|
|
|
14,823 |
|
|
|
11,391 |
|
|
Total operating expenses |
|
|
18,123 |
|
|
|
22,146 |
|
|
|
58,705 |
|
|
|
58,425 |
|
|
Loss from operations |
|
|
(18,123 |
) |
|
|
(22,146 |
) |
|
|
(58,705 |
) |
|
|
(58,425 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
88 |
|
|
|
585 |
|
|
|
549 |
|
|
|
1,711 |
|
|
Other income (expense), net |
|
|
2 |
|
|
|
(12 |
) |
|
|
(23 |
) |
|
|
(45 |
) |
|
Total other income |
|
|
90 |
|
|
|
573 |
|
|
|
526 |
|
|
|
1,666 |
|
|
Net loss |
|
$ |
(18,033 |
) |
|
$ |
(21,573 |
) |
|
$ |
(58,179 |
) |
|
$ |
(56,759 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share, basic and diluted |
|
$ |
(0.29 |
) |
|
$ |
(0.66 |
) |
|
$ |
(1.18 |
) |
|
$ |
(1.80 |
) |
|
Weighted-average common shares outstanding, basic and diluted |
|
|
62,240,412 |
|
|
|
32,894,205 |
|
|
|
49,473,350 |
|
|
|
31,596,321 |
|